Literature DB >> 27004901

Type distribution of myeloid leukemia from Cancer Incidence in Five Continents Vol. X.

Mariko Niino1, Tomohiro Matsuda1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27004901      PMCID： PMC4886143          DOI： 10.1093/jjco/hyw041

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.

Authors:  Takeshi Takahashi; Kensuke Usuki; Kosei Matsue; Hitoshi Ohno; Toru Sakura; Ryota Imanaka; Masato Murakami; Shoichi Ohwada; Taiga Takagi; Sakura Sakajiri
Journal:  Int J Hematol       Date:  2019-08-31       Impact factor: 2.490

2.  Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.

Authors:  Kensuke Usuki; Hiroshi Handa; Ilseung Choi; Takahiro Yamauchi; Hiroatsu Iida; Tomoko Hata; Shoichi Ohwada; Noriko Okudaira; Kota Nakamura; Sakura Sakajiri
Journal:  Int J Hematol       Date:  2019-07-29       Impact factor: 2.490

3.  Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

Authors:  Kazuhito Yamamoto; Atsushi Shinagawa; Courtney D DiNardo; Keith W Pratz; Kenichi Ishizawa; Toshihiro Miyamoto; Norio Komatsu; Yasuhiro Nakashima; Chikashi Yoshida; Noriko Fukuhara; Kensuke Usuki; Takahiro Yamauchi; Noboru Asada; Norio Asou; Ilseung Choi; Yasushi Miyazaki; Hideyuki Honda; Sumiko Okubo; Misaki Kurokawa; Ying Zhou; Jiuhong Zha; Jalaja Potluri; Itaru Matsumura
Journal:  Jpn J Clin Oncol       Date:  2022-01-03       Impact factor: 2.925
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.